Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.
Cytometry A
; 93(9): 916-928, 2018 07.
Article
en En
| MEDLINE
| ID: mdl-30211968
ABSTRACT
Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic disorders. However, the therapies used against the hematopoietic stem cells clones have limited efficacy; they slow the evolution toward acute myeloid leukemia rather than stop clonal evolution and eradicate the disease. The progress made in recent years regarding the role of the bone marrow microenvironment in disease evolution may contribute to progress in this area. This review presents the recent updates on the role of the bone marrow microenvironment in myelodysplastic syndromes pathogenesis and tries to find answers regarding how this information could improve myelodysplastic syndromes diagnosis and therapy.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Médula Ósea
/
Síndromes Mielodisplásicos
/
Microambiente Celular
Tipo de estudio:
Diagnostic_studies
Idioma:
En
Revista:
Cytometry A
Año:
2018
Tipo del documento:
Article